National Test Directory
Would a National Genomics Test Directory advance patient care in Australia?
What is it?
A National Genomics Test Directory is a single, authoritative list of genomic tests available in the health system. It sets out which tests are funded, for which conditions, and ensures consistency across the country.
Why does it matter?
Today, Australians face delays and unequal access to genomic testing, especially for rare diseases and cancer. Decisions about funding are slow and often tied to medicines rather than the value of the test itself. This leaves patients waiting and the system struggling to keep up with rapid advances in genomics.
The UK model:
Since 2018, NHS England’s National Genomic Test Directory has offered patients fast access to over 800 tests. It is updated every year to add new advances and remove outdated tests. This approach has reduced duplication, cut wait times, and ensured patients benefit from the latest science.
What can Australia do?
Australia can adopt a similar model by:
- Funding an evaluation of the UK system.
- Establishing a multi-stakeholder working group (government, clinicians, patients, industry).
- Designing an Australian Genomics Test Directory to deliver fair, timely, and consistent access nationwide.
How could this benefit patients?
- Faster, fairer access to testing for all Australians.
- Better prevention, diagnosis, and personalised care.
- A health system that keeps pace with global innovation and removes wasteful duplication.
